Phase i trials using sleeping beauty to generate CD19-specific CAR T cells

Journal of Clinical Investigation

Volumn 126, Issue 9, 2016, Pages 3363-3376

  Kebriaei, Partow ^a   Singh, Harjeet ^b   Huls, M Helen ^b   Figliola, Matthew J ^b   Bassett, Roland ^b   Olivares, Simon ^b   Jena, Bipulendu ^b   Dawson, Margaret J ^b   Kumaresan, Pappanaicken R ^b   Su, Shihuang ^b   Maiti, Sourindra ^b   Dai, Jianliang ^b   Moriarity, Branden ^c   Forget, Marie Andrée ^b   Senyukov, Vladimir ^b   Orozco, Aaron ^b   Liu, Tingting ^a   McCarty, Jessica ^a   Jackson, Rineka N ^b   Moyes, Judy S ^b   Rondon, Gabriela ^a   Qazilbash, Muzaffar ^a   Ciurea, Stefan ^a   Alousi, Amin ^a   Nieto, Yago ^a   Rezvani, Katy ^a   Marin, David ^a   Popat, Uday ^a   Hosing, Chitra ^a   Shpall, Elizabeth J ^a   Kantarjian, Hagop ^b   Keating, Michael ^b   Wierda, William ^b   Do, Kim Anh ^b   Largaespada, David A ^c   Lee, Dean A ^b,d   Hackett, Perry B ^c   Champlin, Richard E ^a   Cooper, Laurence J N ^b,d,e   more..

^a Division of Cancer Medicine   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e Ziopharm Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; DNA; CYTOKINE; LYMPHOCYTE ANTIGEN RECEPTOR; TRANSPOSON;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL ENGINEERING; CLINICAL ARTICLE; DNA MODIFICATION; ELECTROPORATION; EX VIVO STUDY; GENE EXPRESSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH THROUGHPUT SEQUENCING; HUMAN; MIDDLE AGED; NONHODGKIN LYMPHOMA; NONVIRAL GENE THERAPY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; UPREGULATION; ALLOTRANSPLANTATION; ANTIGEN PRESENTING CELL; CLINICAL TRIAL; CYTOLOGY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GENE THERAPY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; LYMPHOMA, NON-HODGKIN; MALE; METABOLISM; PATIENT SAFETY; PLASMID; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROCEDURES; TRANSPOSON; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD19; CYTOKINES; DISEASE-FREE SURVIVAL; DNA TRANSPOSABLE ELEMENTS; FEMALE; FOLLOW-UP STUDIES; GENETIC THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PATIENT SAFETY; PLASMIDS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84987810063     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI86721     Document Type: Article

References (71)

1. Brentjens RJ, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5(177):177ra38
2. Davila ML, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra25
3. Grupp SA, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509-1518
4. Kalos M, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3(95):95ra73
5. Kochenderfer JN, et al. B-cell depletion and remissions of malignancy along with cytokineassociated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119(12):2709-2720
6. Kochenderfer JN, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33(6):540-549
7. Kochenderfer JN, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010;116(20):4099-4102
8. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725-733
9. Lee DW, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 doseescalation trial. Lancet. 2015;385(9967):517-528
10. Maude SL, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507-1517
11. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18(4):843-851
12. Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther. 2010;18(4):666-668
13. Minagawa K, Zhou X, Mineishi S, Di Stasi A. Seatbelts in CAR therapy: How safe are CARS? Pharmaceuticals (Basel). 2015;8(2):230-249
14. Ivics Z, Hackett PB, Plasterk RH, Izsvak Z. Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell. 1997;91(4):501-510
15. Geurts AM, et al. Gene transfer into genomes of human cells by the sleeping beauty transposon system. Mol Ther. 2003;8(1):108-117
16. Singh H, et al. Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res. 2008;68(8):2961-2971
17. Jena B, Dotti G, Cooper LJ. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood. 2010;116(7):1035-1044
18. Kowolik CM, et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res. 2006;66(22):10995-11004
19. Fielding AK, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2007;109(3):944-950
20. Forman SJ, Rowe JM. The myth of the second remission of acute leukemia in the adult. Blood. 2013;121(7):1077-1082
21. Kebriaei P, Poon LM. The role of allogeneic hematopoietic stem cell transplantation in the therapy of patients with acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2012;7(2):144-152
22. Tavernier E, et al. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia. 2007;21(9):1907-1914
23. Terwey TH, et al. Allogeneic SCT in refractory or relapsed adult ALL is effective without prior reinduction chemotherapy. Bone Marrow Transplant. 2008;42(12):791-798
24. Bachanova V, et al. Impact of pretransplantation (18)F-fluorodeoxy glucose-positron emission tomography status on outcomes after allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2015;21(9):1605-1611
25. Poon LM, et al. Outcomes of adults with acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013;19(7):1059-1064
26. Spyridonidis A, et al. Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT. Leukemia. 2012;26(6):1211-1217
27. Balduzzi A, et al. Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention? Br J Haematol. 2014;164(3):396-408
28. Lankester AC, et al. Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation. Leukemia. 2010;24(8):1462-1469
29. Poon LM, et al. Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia. Bone Marrow Transplant. 2013;48(5):666-670
30. Appelbaum FR. Graft versus leukemia (GVL) in the therapy of acute lymphoblastic leukemia (ALL). Leukemia. 1997;11 Suppl 4:S15-S17
31. Collins RH, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15(2):433-444
32. Passweg JR, et al. Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia. Bone Marrow Transplant. 1998;21(2):153-158
33. Manuri PV, et al. piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies. Hum Gene Ther. 2010;21(4):427-437
34. Huls MH, et al. Clinical application of Sleeping Beauty artificial antigen presenting cells to genetically modify T cells from peripheral umbilical cord blood. J Vis Exp. 2013;(72):e50070
35. Maiti SN, et al. Sleeping beauty system to redirect T-cell specificity for human applications. J Immunother. 2013;36(2):112-123
36. Singh H, Huls H, Kebriaei P, Cooper LJ. A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19. Immunol Rev. 2014;257(1):181-190
37. Singh H, Moyes JS, Huls MH, Cooper LJ. Manufacture of T cells using the Sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptor. Cancer Gene Ther. 2015;22(2):95-100
38. Singh H, et al. Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells. PLoS ONE. 2013;8(5):e64138
39. Denman CJ, et al. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS ONE. 2012;7(1):e30264
40. Zhang M, et al. A new approach to simultaneously quantify both TCR α-and β-chain diversity after adoptive immunotherapy. Clin Cancer Res. 2012;18(17):4733-4742
41. Kebriaei P, et al. Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies. Hum Gene Ther. 2012;23(5):444-450
42. Przepiorka D, et al. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation. Blood. 1996;88(11):4383-4389
43. Luznik L, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and highdose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641-650
44. Wilhelm K, et al. The impact of pre-transplant valganciclovir on early cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation. J Oncol Pharm Pract. 2013;20(4):257-262
45. Kim MT, Harty JT. Impact of inflammatory cytokines on effector and memory CD8+ T cells. Front Immunol. 2014;5:295
46. Miller JS, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105(8):3051-3057
47. Till BG, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood. 2008;112(6):2261-2271
48. Lewalle P, et al. Donor lymphocyte infusions in adult haploidentical transplant: a dose finding study. Bone Marrow Transplant. 2003;31(1):39-44
49. Garfall AL, et al. Chimeric antigen receptor T cells against CD19 for multiple myeloma. N Engl J Med. 2015;373(11):1040-1047
50. Nellan A, Lee DW. Paving the road ahead for CD19 CAR T-cell therapy. Curr Opin Hematol. 2015;22(6):516-520
51. Yang Y, Jacoby E, Fry TJ. Challenges and opportunities of allogeneic donor-derived CAR T cells. Curr Opin Hematol. 2015;22(6):509-515
52. Jacoby E, Yang Y, Qin H, Chien CD, Kochenderfer JN, Fry TJ. Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD. Blood. 2016;127(10):1361-1370
53. Di Stasi A, et al. Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors. Biol Blood Marrow Transplant. 2014;20(12):1975-1981
54. Martin PJ, et al. First-and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2012;18(8):1150-1163
55. Cruz CR, et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood. 2013;122(17):2965-2973
56. Brudno JN, et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J Clin Oncol. 2016;34(10):1112-1121
57. Sauter CS, et al. Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma. Blood. 2015;125(16):2579-2581
58. Symons HJ, et al. Haploidentical BMT using fully myeloablative conditioning, T cell replete bone marrow grafts, and post-transplant cyclophosphamide (PT/Cy) has limited toxicity and promising efficacy in largest reported experience with high risk hematologic malignancies. Biol Blood Marrow Transplant. 2015;21(2):S29
59. Savoldo B, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest. 2011;121(5):1822-1826
60. Porter DL, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015;7(303):303ra139
61. Kim HO, Kim HS, Youn JC, Shin EC, Park S. Serum cytokine profiles in healthy young and elderly population assessed using multiplexed bead-based immunoassays. J Transl Med. 2011;9:113
62. Kleiner G, Marcuzzi A, Zanin V, Monasta L, Zauli G. Cytokine levels in the serum of healthy subjects. Mediators Inflamm. 2013;2013:434010
63. Jonnalagadda M, et al. Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy. Mol Ther. 2015;23(4):757-768
64. Hackett PB, Largaespada DA, Switzer KC, Cooper LJ. Evaluating risks of insertional mutagenesis by DNA transposons in gene therapy. Transl Res. 2013;161(4):265-283
65. Izsvak Z, Hackett PB, Cooper LJ, Ivics Z. Translating Sleeping Beauty transposition into cellular therapies: victories and challenges. Bioessays. 2010;32(9):756-767
66. Jensen MC, et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant. 2010;16(9):1245-1256
67. Till BG, et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood. 2012;119(17):3940-3950
68. Huang X, et al. Stable gene transfer and expression in human primary T cells by the Sleeping Beauty transposon system. Blood. 2006;107(2):483-491
69. Mates L, et al. Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nat Genet. 2009;41(6):753-761
70. Rahrmann EP, et al. Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. Nat Genet. 2013;45(7):756-766
71. Dinse GE, Lagakos SW. Nonparametric estimation of lifetime and disease onset distributions from incomplete observations. Biometrics. 1982;38(4):921-932